6b73
From Proteopedia
(Difference between revisions)
(2 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
==Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor== | ==Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor== | ||
- | <StructureSection load='6b73' size='340' side='right' caption='[[6b73]], [[Resolution|resolution]] 3.10Å' scene=''> | + | <StructureSection load='6b73' size='340' side='right'caption='[[6b73]], [[Resolution|resolution]] 3.10Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[6b73]] is a 4 chain structure with sequence from [ | + | <table><tr><td colspan='2'>[[6b73]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Escherichia_coli Escherichia coli], [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Lama_glama Lama glama]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6B73 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6B73 FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=CVV:N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide'>CVV</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 3.1Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=CVV:N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3-hydroxy-7,8-didehydro-4,5-epoxymorphinan-6-yl]-3-iodobenzamide'>CVV</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene></td></tr> | |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6b73 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6b73 OCA], [https://pdbe.org/6b73 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6b73 RCSB], [https://www.ebi.ac.uk/pdbsum/6b73 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6b73 ProSAT]</span></td></tr> |
</table> | </table> | ||
== Function == | == Function == | ||
- | [ | + | [https://www.uniprot.org/uniprot/C562_ECOLX C562_ECOLX] Electron-transport protein of unknown function.[https://www.uniprot.org/uniprot/OPRK_HUMAN OPRK_HUMAN] G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions.<ref>PMID:12004055</ref> <ref>PMID:22437504</ref> <ref>PMID:7624359</ref> <ref>PMID:8060324</ref> |
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
Line 19: | Line 19: | ||
</div> | </div> | ||
<div class="pdbe-citations 6b73" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 6b73" style="background-color:#fffaf0;"></div> | ||
+ | |||
+ | ==See Also== | ||
+ | *[[Antibody 3D structures|Antibody 3D structures]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Escherichia coli]] |
- | [[Category: | + | [[Category: Homo sapiens]] |
- | [[Category: Carroll | + | [[Category: Lama glama]] |
- | [[Category: Che | + | [[Category: Large Structures]] |
- | [[Category: Cherezov | + | [[Category: Carroll IF]] |
- | [[Category: Han | + | [[Category: Che T]] |
- | [[Category: Huang | + | [[Category: Cherezov V]] |
- | [[Category: Katritch | + | [[Category: Han GW]] |
- | [[Category: Kormos | + | [[Category: Huang XP]] |
- | [[Category: Krumm | + | [[Category: Katritch V]] |
- | [[Category: Lee | + | [[Category: Kormos C]] |
- | [[Category: Majumdar | + | [[Category: Krumm BE]] |
- | [[Category: McCorvy | + | [[Category: Lee MY]] |
- | [[Category: Mosier | + | [[Category: Majumdar S]] |
- | [[Category: Pardon | + | [[Category: McCorvy JD]] |
- | [[Category: Pasternak | + | [[Category: Mosier PD]] |
- | [[Category: Roth | + | [[Category: Pardon E]] |
- | [[Category: Stevens | + | [[Category: Pasternak GW]] |
- | [[Category: Steyaert | + | [[Category: Roth BL]] |
- | [[Category: Strachan | + | [[Category: Stevens RC]] |
- | [[Category: Tribo | + | [[Category: Steyaert J]] |
- | [[Category: Uprety | + | [[Category: Strachan RT]] |
- | [[Category: Vardy | + | [[Category: Tribo AR]] |
- | [[Category: Wacker | + | [[Category: Uprety R]] |
- | [[Category: Wang | + | [[Category: Vardy E]] |
- | [[Category: Zaidi | + | [[Category: Wacker D]] |
- | + | [[Category: Wang S]] | |
- | + | [[Category: Zaidi SA]] | |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + |
Current revision
Crystal Structure of a nanobody-stabilized active state of the kappa-opioid receptor
|
Categories: Escherichia coli | Homo sapiens | Lama glama | Large Structures | Carroll IF | Che T | Cherezov V | Han GW | Huang XP | Katritch V | Kormos C | Krumm BE | Lee MY | Majumdar S | McCorvy JD | Mosier PD | Pardon E | Pasternak GW | Roth BL | Stevens RC | Steyaert J | Strachan RT | Tribo AR | Uprety R | Vardy E | Wacker D | Wang S | Zaidi SA